IMPACT OF ENZALUTAMIDE OR ABIRATERONE ACETATE plus PREDNISONE (AbP) ON QUALITY OF LIFE (QoL) IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (mCRPC) THAT HAS PROGRESSED ON OR AFTER DOXETAXEL: A COMPARATIVE EFFECTIVENESS STUDY

被引：1

作者：

Cella, D. ^{[1
]}

Ivanescu, C. ^{[2
]}

Phung, D. ^{[3
]}

Mansbach, H. ^{[4
]}

Holmstrom, S. ^{[5
]}

Naidoo, S. ^{[6
]}

机构：

[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA

[2] Quintiles, Hoofddorp, Netherlands

[3] Astellas Pharma Europe, Leiden, Netherlands

[4] Medivation Inc, San Francisco, CA USA

[5] Astellas Pharma Europe BV, Leiden, Netherlands

[6] Astellas Pharma EMEA, Chertsey, England

来源：

关键词：

D O I：

10.1016/j.jval.2015.03.1222

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PCN125

引用

页码：A211 / A211

页数：1